Business Context and Reporting Period
This Form 8-K Current Report from SANUWAVE Health, Inc. (SNWV) covers events occurring on September 25, 2025. The filing details significant changes to the Company's executive leadership structure, including the appointment of a new Chief Operating Officer, the reassignment of a former officer, and the termination of the President.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensatory arrangements rather than financial performance.
Material Changes and Personnel Actions
- Appointment of Chief Operating Officer: Daniel Coyle was appointed Chief Operating Officer (COO) effective September 25, 2025. He previously served as Vice President of Engineering and Operations.
- Compensation for New COO: Mr. Coyle's annualized base salary was increased to $225,000. His annual cash bonus opportunity for the remainder of 2025 was set at 40% of his base salary. Additionally, he was granted stock options to purchase 60,000 shares, vesting in 12 equal quarterly installments starting October 9, 2025.
- Reassignment of Former COO: Peter Stegagno was removed from the position of COO and appointed Chief Regulatory Officer. The Board determined he no longer meets the definition of an "officer" or "executive officer" under the Exchange Act.
- Termination of President: Andrew Walko, the Company's President, was terminated without cause, effective October 24, 2025. A separation agreement is currently under negotiation.
- Leadership Vacuum: The Company does not intend to appoint a new President at this time.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed is the uncertainty surrounding the leadership transition, specifically the pending negotiation of a separation agreement for the terminated President and the absence of a designated President.
Key Facts for Investor Verification
- Verify the final terms of the separation agreement for Andrew Walko, as they are not yet finalized.
- Confirm the operational impact of having no designated President while the COO role is newly filled.
- Monitor the vesting schedule and potential dilution from the 60,000 stock options granted to Daniel Coyle.
- Review subsequent filings for any further changes to the executive team or the status of the President's role.